Overview

Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the survival benefit and safety of cytoreductive surgery(CRS) combined with HIPEC and chemotherapy in gastric cancer with peritoneal metastasis.
Phase:
Phase 3
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Treatments:
Capecitabine
Cisplatin
Fluorouracil